Autophagic Pathways to Clear the Tau Aggregates in Alzheimer’s Disease

被引:0
|
作者
Nalini Vijay Gorantla
Subashchandrabose Chinnathambi
机构
[1] CSIR-National Chemical Laboratory (CSIR-NCL),Neurobiology Group, Division of Biochemical Sciences
[2] Academy of Scientific and Innovative Research (AcSIR),undefined
来源
关键词
Alzheimer’s disease; Tau; Neurofibrillary tangles; Tau degradation; Ubiquitin–proteasome system; Macroautophagy; Chaperone-mediated autophagy; Lysosome-associated membrane proteins-2A;
D O I
暂无
中图分类号
学科分类号
摘要
Tau is a microtubule-associated protein with an intrinsically unstructured conformation. Tau is subjected to several pathological post-translational modifications (PTMs), leading to its loss of interaction with microtubules and accumulation as neurofibrillary tangles (NFTs) in neurons. Tau aggregates impede functions of endoplasmic reticulum and mitochondria leading to the generation of oxidative stress and in turn amplifying the Tau aggregation. Tau is channelled to chaperones for folding into their native form, which otherwise causes its degradation and clearance. Cellular response triggers the activation of ubiquitin–proteasome system or autophagy to facilitate Tau degradation, based on the PTMs or mutations associated with Tau. Further, autophagy can be selective where Hsc70 interacts with Tau in monomeric, oligomeric and aggregated form and drives its clearance by chaperone-mediated autophagy pathway (CMA). Lysosome-associated membrane proteins-2A (LAMP-2A) is the key player of CMA that recognises Hsc70-Tau complex and triggers the downstream cascade. Thus, it becomes challenging for mutant Tau to be cleared by CMA as it loses its affinity for Hsc70 and LAMP-2A. In such a scenario, Tau might be degraded by macroautophagy otherwise sequestered by aggresomes. Henceforth, the degradation of Tau and its blockage that is associated with various PTMs of Tau would explain the dynamics of Tau degradation or accumulation in AD. Further, unveiling the role of accessory proteins involved in these degradation pathways would help in understanding their loss of function and preventing Tau clearance.
引用
收藏
页码:1175 / 1181
页数:6
相关论文
共 50 条
  • [21] NPT001: A candidate therapeutic for clearance of β-amyloid and tau aggregates in Alzheimer's Disease
    Fisher, R.
    Gannon, K. S.
    Krishnan, R.
    Tsubery, H.
    Lulu, M.
    Gartner, M.
    Gilead, S.
    Proschitsky, M.
    Wright, J.
    Rockenstein, E.
    Masliah, E.
    Solomon, B.
    [J]. JOURNAL OF MOLECULAR NEUROSCIENCE, 2012, 48 : S118 - S119
  • [22] Tau, tangles, and Alzheimer's disease
    Binder, LI
    Guillozet-Bongaarts, AL
    Garcia-Sierra, F
    Berry, RW
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2005, 1739 (2-3): : 216 - 223
  • [23] Tau phosphorylation in Alzheimer's disease
    Hanger, D
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S100 - S100
  • [24] The role of tau in Alzheimer's disease
    Trojanowski, JQ
    Lee, VMY
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2002, 86 (03) : 615 - +
  • [25] Dendritic Tau in Alzheimer's Disease
    Ittner, Arne
    Ittner, Lars M.
    [J]. NEURON, 2018, 99 (01) : 13 - 27
  • [26] Tau immunotherapies for Alzheimer's disease
    Hoskin, Justin L.
    Sabbagh, Marwan Noel
    Al-Hasan, Yazan
    Decourt, Boris
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (06) : 545 - 554
  • [27] Tau protein and Alzheimer's disease
    Kosik, K. S.
    [J]. CURRENT OPINION IN CELL BIOLOGY, 1990, 2 (01) : 101 - 104
  • [28] Aluminium, tau and Alzheimer's disease
    Exley, Christopher
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2007, 12 (04) : 313 - 315
  • [29] The complexity of tau in Alzheimer's disease
    Naseri, Nima N.
    Wang, Hong
    Guo, Jennifer
    Sharma, Manu
    Luo, Wenjie
    [J]. NEUROSCIENCE LETTERS, 2019, 705 : 183 - 194
  • [30] Tau Ubiquitination in Alzheimer's Disease
    Li, Longfei
    Jiang, Yanli
    Wang, Jian-Zhi
    Liu, Rong
    Wang, Xiaochuan
    [J]. FRONTIERS IN NEUROLOGY, 2022, 12